[Edaily Reporter Shin Ha-yeon ] Financial information provider FnGuide Inc.(064850)announced on the 7th that it has appointed Jeon Min-seok, Head of the Business Strategy Division (Vice President), as its new CEO and has transitioned to a co-CEO system.
FnGuide Inc. appointed Mr. Jeon as the new CEO at a board meeting held on the 6th. Consequently, the company has shifted from the previous system of sole CEO Lee Ki-tae to a co-CEO system in which CEOs Lee Ki-tae and Jeon Min-seok will jointly lead the company. The company plans to strengthen accountable management and improve operational efficiency.
After serving in sales and sales planning roles at Nongshim and LF, CEO Jeon joined FnGuide Inc., where he has led the Business Strategy Division and overseen management functions—including human resources and finance—as well as investor relations (IR).
While strengthening communication with investors, he has driven the development of new businesses and business expansion based on collaboration with key clients and partners, and has also led the advancement of AI-based financial information services and the company’s digital transformation.
A representative of FnGuide Inc. stated, “We expect CEO Jeon Min-seok, drawing on the experience and expertise he has accumulated over the years, to contribute to the company’s sustained growth and enhanced future competitiveness alongside CEO Lee Ki-tae.” Jeon Min-seok, the new CEO of FnGuide Inc. (Photo courtesy of FnGuide Inc.)
(Photo: Blind)
One of the concerns facing the Lee Jae-myung administration is the decline in support among young people. According to Gallup Korea’s presidential job approval ratings, the approval…
The KRX Health Care Index rose 4.53% from the previous session on Oct. 1, signaling a rare tailwind for South Korea’s pharmaceutical and biotech sector. Among the gainers, GIInnovation and G2GBio drew…
(Graphic: ChatGPT)
“While existing ex vivo chimeric antigen receptor T-cell (CAR-T) therapies are personalized treatments that require cell collection from each patient for manufacturing, the in v…